摘要
Objective： To evaluate the effect of anti-vascular endothelial growth factor （VEGF） on juxtafoveal choroidal neovascularization （CNV） secondary to multifocal choroiditis （MFC） and wet age-related macular degeneration （AMD）. Methods： In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups： 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal （Ivr） injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Results： Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy （P〈0.05）. The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients （Z=-2.844, P=0.009）. Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy （P〈0.05）, and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later （P〉0.05）. Conclusions： IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
目的:比较抗血管内皮生长因子(VEGF)药物对多灶性脉络膜炎(MFC)和湿性老年性黄斑变性(AMD)的疗效。创新点:MFC是一种特发性脉络膜视网膜病变,容易并发多灶性脉络膜新生血管,治疗棘手,易复发。目前有个别病例报道证明抗VEGF对其新生血管的治疗有效果,但是缺少更多的数据比较。本文将抗VEGF药物对MFC和AMD的疗效进行对比,以了解其在不同疾病中的疗效。方法:收集MFC并发络膜新生血管和AMD并发络膜新生血管患者各10名,予以玻璃体腔注射抗VEGF药物,跟踪随访患者6个月的视力变化、新生血管大小、黄斑水肿情况。随访期间采用眼底血管造影以及光学相干断层扫描进行监测,如发现有活动性脉络膜新生血管,予以再次注射。结论:抗VEGF药物对MFC并发的脉络膜新生血管有良好的治疗效果,注射次数少于湿性AMD并发的新生血管治疗,且视力恢复情况也较其明显。
基金
Project supported by the National Natural Science Foundation of China(No.81500760)
